Therorna

Therorna was founded in China in 2021, leveraging its proprietary circular RNA technology platform to develop next-generation vaccines and innovative therapies.

Compared with linear RNA, circular RNA (circRNA) offers benefits in expression, stability, immunogenicity, and production. Thanks to its structure, circRNA as a tool for protein expression has been proven to maintain a relatively stable protein expression level in vivo for a longer time, which is expected to expand the application scenarios of RNA therapy.

Therorna raised Series A funding in June 2022 to help accelerate the development of a new broad-spectrum COVID-19 vaccine and the discovery of additional novel therapies for a variety of diseases. The company says it has already established a strong pipeline of novel prophylactic and therapeutic drugs aiming to address high unmet medical needs.

The company’s founder Wensheng Wei is a Professor at Peking University and previously also founded genome editing company EdiGene.

Subscribe for alerts on new companies featured on Startups.Bio

Archon Biosciences
Archon Biosciences is a biotech company pioneering computationally designed 'Antibody Cages' to unlock powerful therapeutic targets beyond the reach of existing modalities. Archon directly applies generative protein design to rapidly …
Cytospire Therapeutics
Founded in 2023, Cytospire Therapeutics is developing a portfolio of next-generation immune cell engagers for treating cancer. The company's multispecific antibodies are designed to harness and direct the power of …
This Week in Biotech Venture Capital
The biotech sector continues to see a strong flow of new venture capital deals, with a flurry of new announcements this week. We saw a diverse set of companies—ranging from …
THRONCAT
THRONCAT is a new startup that aims to transform the field of protein analysis and mRNA therapeutics safety. THRONCAT began with a mission to make protein analysis more accessible and …

View all recently featured startups

Tags: